Page 14 - Pharma Stocks

Moderation in earnings growth may weigh on equities this year: Vinit Sambre

Sambre says while equities may do well in the long-term, it would be prudent for investors to reassess their asset allocation and bring it in line with their risk profile

Moderna reports surprise Q4 profit, sets out road map for RSV vaccine

Moderna recorded $6.8 billion in sales from its COVID vaccine in 2023, down from $18.4 billion in 2022 but slightly above Wall Street estimates of $6.7 billion

Medplus slips 2% after board defers expansion plan of diagnostics division

The company's board on Wednesday decided to defer the expansion plans for Diagnostics Division beyond Hyderabad, until the profitability of the pilot project was established.

Novartis soars 11%; board to support parent firm explore strategic options

According to reports, Dr Reddy's Laboratories is likely in a race to acquire Novartis AG's stake in Novartis India.

This Mukul Agrawal-owned pharma stock has zoomed over 200% in 9 months

Neuland Lab hit a new high of Rs 6,910, rallied 6% after reported robust earnings with profit after tax more than doubled to Rs 80.7 crore in Q3FY24, on back of healthy operational performance.

Lupin soars 7%, trades at highest level since Aug 2016 on strong Q3 results

The company's profit jumped nearly 300 per cent to Rs 613 crore for the December 2023 quarter from a year ago period.

Sun Pharma Advanced Research freezes at 10% upper circuit; up 64% in 8 days

In the medium term, SPARC's pipeline has several inflexion points that can drive significant value for the company.

Stock of this pharma company has nearly doubled against its issue price

Mankind hit record high of Rs 2,132.10, rallied 8% in intra-day trade and zoomed 97% against its issue price of Rs 1,080 per share.

As Covid-19 cases rise in India; should you keep pharma stocks on radar?

Barring Dr Lal Pathlabs, the other four healthcare related stocks listed below seem to be trapped in a range for now, charts suggest.

GSK Pharma surges 7%, nears record high on healthy business outlook

Since November, the stock has appreciated by 36% after the company reported earnings improvement in Q2FY24 on strong demand for its vaccines and general medicine.

Aurobindo Pharma's new injectable facility get 10 observations from US FDA

"The observations are procedural and will be responded to within the stipulated time," the company stated in a regulatory filing

Nifty Metal eyes consolidation, Nifty Pharma trades with negative bias

The advised strategy for the Nifty Metal index is to buy near support levels and sell near resistance

Laurus Labs slips 4% as arm gets 5 observations post USFDA inspection

Laurus Synthesis Private Limited has been issued a Form 483 with five observations and the company plans to address the observations within stipulated timelines.

Lupin Ltd receives USFDA approval for smoking cessation drug Chantix

The product will be manufactured at Lupin's Pithampur facility in India, the company said in a regulatory filing

Aurobindo Pharma hits 52-week high, jumps nearly 4% in a weak market

The stock has been one of the top out-performers so far this month, and gained a whopping 18.5 per cent.

Biocon jumps 4% on the back of strong Q2 performance

The stock had shed 16 per cent in Samvat 2079. So far in 2023, the stock has declined 9 per cent as against a near 7 per cent gain on the BSE benchmark.

Cipla Q2 net profit seen rising 25% YoY; US sales may drop QoQ to $215 mn

Cipla Q2FY24 result preview: On a sequential basis (QoQ), Cipla's net profit is seen declining 1.1 per cent, while revenue may grow 2.2 per cent

Biocon slips 4% after USFDA asks for corrective measures at Malaysian unit

The USFDA has determined the inspection classification as 'OAI' (Official Action Indicated) post inspection of Biocon's step-down subsidiary in Malaysia.

Glenmark Pharma soars 10% after S&P Global upgrades outlook to positive

The rating agency expects Glenmark to significantly reduce debt on completion of the GLS sale and maintain healthy earnings.

Bajaj Healthcare zooms 53% in four weeks on healthy FY24 guidance

EBITDA margins would be in the range of 16 -20 per cent for the FY24, mainly driven by growth in the formulation biz and with the introduction of reverse engineering APIs launched in the last fiscal.